Dracen Pharmaceuticals
Baltimore
About Dracen Pharmaceuticals
Dracen Pharmaceuticals is a developer of novel glutamine antagonists created to deliver improved outcomes for cancer patients and potentially extend the benefits of immuno-oncology therapies. The company develops novel glutamine antagonists with direct anti-tumor apoptotoc properties as well as endogenous anti-tumor immune modulatory mechanisms which increases the number of responders to anti-cancer therapy and extend survival for anti-tumor responses in areas currently evading immuno-oncology approaches.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Total funding: $50.9M
- Last round: Debt Financing (Aug 2023)
- Website: dracenpharma.com
- Phone: (917) 398-3710
Industries & Categories
Health Care, Pharmaceutical
Social Profiles
Canonical: https://fsome.com/organization/dracen-pharmaceuticals-174714 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.